Machina Capital S.A.S. trimmed its position in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 51.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,993 shares of the biopharmaceutical company’s stock after selling 14,870 shares during the quarter. Machina Capital S.A.S.’s holdings in Bristol Myers Squibb were worth $873,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Davis Asset Management L.P. acquired a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $27,000. Addison Advisors LLC acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth about $32,000. William Mack & Associates Inc. acquired a new stake in Bristol Myers Squibb during the third quarter worth approximately $35,000. Groupe la Francaise grew its position in shares of Bristol Myers Squibb by 562.9% in the second quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 501 shares during the period. Finally, Kilter Group LLC purchased a new stake in Bristol Myers Squibb in the 2nd quarter valued at about $35,000. Institutional investors and hedge funds own 76.41% of the company’s stock.
Analyst Ratings Changes
A number of research firms have recently commented on BMY. Rothschild & Co Redburn raised their price objective on Bristol Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th. Cantor Fitzgerald cut their price target on Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating on the stock in a research note on Thursday, October 8th. Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 13th. Daiwa Securities Group raised their price target on shares of Bristol Myers Squibb from $53.00 to $66.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Finally, Truist Financial set a $70.00 price objective on Bristol Myers Squibb in a research report on Friday, October 30th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $65.46.
Get Our Latest Research Report on Bristol Myers Squibb
Insider Buying and Selling
In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. The trade was a 2.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Julia Haller sold 3,800 shares of the business’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the sale, the director directly owned 30,279 shares in the company, valued at $1,916,963.49. This trade represents a 11.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.05% of the stock is owned by company insiders.
Key Stories Impacting Bristol Myers Squibb
Investors following BMY have been watching these stories:
- Positive Sentiment: Bristol Myers is working to expand Camzyos’ reach, while Eliquis remains an important contributor to its cardiovascular franchise. Sustained growth in these products could help support revenue. Can BMY Sustain Growth in Its Cardiovascular Franchise?
- Neutral Sentiment: The company plans to unify research and development under one structure, aiming to bring scientific and clinical teams together to speed development and use new technologies. The departure of research chief Robert Plenge adds transition risk, so the impact will depend on execution. BMS sets unified research and development structure for 2027
- Negative Sentiment: Zacks Research cut several earnings forecasts, including FY2026 EPS to $6.44 from $6.86 and FY2028 EPS to $4.77 from $5.21; it also reduced its Q4 2026 and Q2 2027 estimates. These revisions point to a softer earnings outlook, although the firm maintained a Hold rating. Bristol Myers Squibb analyst estimates
Bristol Myers Squibb Stock Performance
NYSE:BMY opened at $63.39 on Monday. The company has a current ratio of 1.59, a quick ratio of 1.44 and a debt-to-equity ratio of 1.79. The firm’s fifty day simple moving average is $61.90 and its 200 day simple moving average is $60.31. The firm has a market capitalization of $129.57 billion, a PE ratio of 14.06, a PEG ratio of 0.33 and a beta of 0.20. Bristol Myers Squibb Company has a 1 year low of $45.26 and a 1 year high of $68.64.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The business had revenue of $13.07 billion for the quarter, compared to analyst estimates of $12.72 billion. During the same period in the prior year, the company earned $1.63 EPS. Bristol Myers Squibb’s revenue for the quarter was up 6.9% on a year-over-year basis. On average, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.46 EPS for the current year.
Bristol Myers Squibb Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.0%. The ex-dividend date of this dividend was Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.88%.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
Featured Articles
- Five stocks we like better than Bristol Myers Squibb
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
